Showing results (591-600 of 627) with videos related to
Sort By:
Pageof 63
Circulation. Arrhythmia and Electrophysiology|September 27, 2021
Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch: Findings From the Apple Heart StudyAlexander C Perino, Santosh E Gummidipundi, Justin Lee, et al.Circulation|July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsKenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.Journal of the American College of Cardiology|May 9, 2020
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES TrialDeepak L Bhatt, Andrew H Briggs, Shelby D Reed, et al.Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
Leveraging Deep Learning of Chest Radiograph Images to Identify Individuals at High Risk for Chronic Obstructive Pulmonary DiseaseSaman Doroodgar Jorshery, Jay Chandra, Anika S Walia, et al.Journal of the American College of Cardiology|February 14, 1998
Myonecrosis after revascularization proceduresR M Califf, A E Abdelmeguid, R E Kuntz, et al.The New England Journal of Medicine|March 12, 2013
Effect of platelet inhibition with cangrelor during PCI on ischemic eventsDeepak L Bhatt, Gregg W Stone, Kenneth W Mahaffey, et al.Circulation|May 24, 2019
Effect of Alirocumab on Mortality After Acute Coronary SyndromesPhilippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, et al.American Journal of Medicine Open|April 1, 2025
Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study ExperienceNeha Pagidipati, Brooke Heidenfelder, Lydia Coulter Kwee, et al.Circulation|February 8, 2021
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE TrialNan Ye, Meg J Jardine, Megumi Oshima, et al.Biorxiv : the Preprint Server for Biology|June 4, 2026
Immune Aging is an Independent Risk Factor for Cardiovascular DiseaseErik Feldman, Everton Jose Santana, Bettia Celestin, et al.Pageof 63